放疗联合替加氟栓同步治疗中晚期食管癌的临床研究

Clinical Effects of Radiotherapy Combined with Tegafur Suppository Treatment for Mid-to Late-Stage Esophageal Cancer

目的观察放疗联合替加氟栓同步治疗中晚期食管癌的疗效及副作用。方法将初治中晚期食管鳞癌89例,随机分为放化组与单放组,放疗采用6MV-X常规分割,1.8～2.0 Gy次/,5次/周,总剂量60～70 Gy,6～7周完成。放疗同步应用替加氟栓500 mg粒/,每天1次,直肠给药,全程使用。结果放化组与单放组有效率、完全缓解率、部分缓解率分别为93.5%、52.2%、41.3%和72.1%、37.2%、34.9%;1、2、3年生存率分别为73.9%、54.3%、41.3%和55.8%、39.5%、18.6%,两组比较有显著性差异,P<0.05。放化组白细胞下降,胃肠道反应与直肠反应发生率均高于单放组,大多数为1～2级。结论对中晚期食管癌患者替加氟栓直肠给药联合放疗方便安全,吸收好,疗效好,副作用相对较轻。

Objective To evaluate the effects of radiotherapy combined with Tegafur suppository treatment for mid-to late-stage esophageal cancer. Methods 89 patients with mid- to late-stage esophageal cancer were randomly divided into two groups ：one group was treated with radiotherapy combined with Tegafur suppository （CRT） ; the other group was treated with radiotherapy alone （RT）. Radiotherapy was delivered in 1.8 - 2.0 Gy/fraction with a total dose of 60 - 70 Gy over the course of 6 - 7 weeks. 500mg per capsule Tegafur Suppository was delivered into the rectum during the course of radiotherapy. Results The response rate,complete response rate, and partial response rate in the CRT group were 93.5%, 52.2% ,41.3%, and 72.1%, 37.2% ,and 34.9% in the RT alone group. The 1,2,and 3-year survival rate was 73.9% ,54.3% , and 41.3% for patients received CRT, and 55.8% ,39.5 % , and 18.6% for patients received RT alone. There was statistically significant difference （P 〈 0.05 = between the two groups. Major toxicities （mostly in Grade I or II） such as myelosupperession, acute gastrointestinal reactions,and rectum reactions in CRT was higher than that in RT. Conclusion Radiotherapy combined with Tegafur suppository treatment was a safe and convenient approach for patients with midto late-stage esophageal cancer.